share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
SEC announcement ·  03/26 16:16
Moomoo AI 已提取核心信息
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
2024年3月26日，处于临床阶段的生物制药公司Panbela Therapeutics, Inc. 发布了一份新闻稿，公布了截至2023年12月31日的年度财务业绩。该公告通过8-K表格向美国证券交易委员会提交，重点介绍了该公司的业务更新，包括临床试验进展和财务里程碑。Panbela报告称，2023年第四季度净亏损650万美元，摊薄每股亏损65.90美元，而2022年同期净亏损470万美元，摊薄每股亏损344.61美元。研发费用从同比的350万美元增加到610万美元。该公司还于2024年1月31日完成了公开募股，筹集了约900万美元。Panbela的研发项目包括以各种癌症和糖尿病为重点的临床...展开全部
2024年3月26日，处于临床阶段的生物制药公司Panbela Therapeutics, Inc. 发布了一份新闻稿，公布了截至2023年12月31日的年度财务业绩。该公告通过8-K表格向美国证券交易委员会提交，重点介绍了该公司的业务更新，包括临床试验进展和财务里程碑。Panbela报告称，2023年第四季度净亏损650万美元，摊薄每股亏损65.90美元，而2022年同期净亏损470万美元，摊薄每股亏损344.61美元。研发费用从同比的350万美元增加到610万美元。该公司还于2024年1月31日完成了公开募股，筹集了约900万美元。Panbela的研发项目包括以各种癌症和糖尿病为重点的临床试验，其主要资产是Ivospemin（SBP-101）和Flynpovi。该公司针对未经治疗的转移性胰腺导管腺癌的ASPIRE试验的入组人数已超过50％，预计到2025年第一季度将全部入组。Panbela的股票在纳斯达克股票市场有限责任公司上市，股票代码为 “PBLA”。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息